The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL12 2022 | The challenges with treating high-risk patients with HL: a Brazilian perspective
Irene Biasoli, MD, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, shares some insights into the challenges with treating high-risk patients with advanced-stage Hodgkin lymphoma (HL) in Brazil. Dr Biasoli highlights why clinicians most frequently use ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) as frontline treatment for HL patients, and further comments on the need to improve access to novel agents such as brentuximab vedotin. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
